Evolus (EOLS) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evolus (EOLS) has outperformed Oculis (OCS) over the past year, gaining 25.6% versus a loss of 55.4%. Over five years, EOLS leads with a +0.9% price change compared with -13.4% for OCS. Oculis is the larger company by market cap ($533.4 million vs $515.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | OCS |
|---|---|---|
| Share price | $7.80 | $8.66 |
| Market cap | $515.19M | $533.35M |
| 1-day change | +0.78% | +1.88% |
| YTD return | +17.29% | -57.44% |
| 1-year return | +25.60% | -55.40% |
| 5-year return | +0.91% | -13.44% |
| Forward P/E | 26.67 | — |
| EPS (TTM) | $-0.53 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $34.48 |
| 52-week low | $3.86 | $8.30 |
| Distance from 52-week high | -16.22% | -74.88% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +92.31% | +321.36% |
| Average volume | 896.67K | 258.13K |
| Shares outstanding | 66.05M | 61.59M |
| Employees | 353 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed OCS by 81.0 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
EOLS vs OCS FAQ
Which is bigger, Evolus or Oculis?
Oculis (OCS) is larger, with a market capitalization of $533.35M compared with $515.19M for Evolus (EOLS).
Which stock has performed better over the past year, EOLS or OCS?
EOLS returned +25.60% over the past 12 months, compared with -55.40% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Oculis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.